Placid Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-07-2024
- Paid Up Capital ₹ 0.10 M
as on 24-07-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.33 Cr
as on 24-07-2024
- Satisfied Charges ₹ 1.43 Cr
as on 24-07-2024
- Revenue -13.40%
(FY 2023)
- Profit -22.91%
(FY 2023)
- Ebitda -16.99%
(FY 2023)
- Net Worth 5.66%
(FY 2023)
- Total Assets 3.48%
(FY 2023)
About Placid Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.33 Cr. The company has closed loans amounting to ₹1.43 Cr, as per Ministry of Corporate Affairs (MCA) records.
Parikshit Jain, Purnima Jain, and Pooja Jain serve as directors at the Company.
- CIN/LLPIN
U24233MH2010PTC210052
- Company No.
210052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Placid Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parikshit Jain  | Director | 15-Nov-2010 | Current |
| Purnima Jain | Director | 01-Feb-2019 | Current |
| Pooja Jain | Director | 15-Nov-2010 | Current |
Financial Performance and Corporate Structure Insights of Placid Pharmachem.
Placid Pharmachem Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.4% decrease. The company also saw a substantial fall in profitability, with a 22.91% decrease in profit. The company's net worth moved up by a moderate rise of 5.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Placid Pharmachem?
In 2023, Placid Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vijaya Sai Laboratories India Private LimitedActive 14 years 5 monthsParikshit Jain is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Nov 2021 | ₹1.10 M | Open |
Hdfc Bank Limited Creation Date: 12 Jul 2021 | ₹9.22 Cr | Open |
Icici Bank Limited Creation Date: 24 Apr 2012 | ₹9.90 M | Satisfied |
How Many Employees Work at Placid Pharmachem?
Unlock and access historical data on people associated with Placid Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Placid Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Placid Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
